¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇÑÁ¾¾ç³»°úÇÐȸ (¿Â¶óÀÎ) Best of ASCO 2021 in Korea : 2021-08-20

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇÑÁ¾¾ç³»°úÇÐȸ (¿Â¶óÀÎ) Best of ASCO 2021 in Korea : 2021-08-20
±³À°ÀÏÀÚ : 2021-08-20
±³À°Àå¼Ò : ¿Â¶óÀÎ ¿¬¼ö±³À°(½Ç½Ã°£)  
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) Best of ASCO 2021 in Korea
ÁÖÃÖ±â°ü : ´ëÇÑÁ¾¾ç³»°úÇÐȸ(17.5 ¸íĪº¯°æ Çѱ¹ÀÓ»ó¾ÏÇÐȸ)
´ã´çÀÚ : ´ëÇÑÁ¾¾ç³»°úÇÐȸ
¿¬¶ôó : 02-735-2857  
À̸ÞÀÏ : ksmo3@ksmo.or.kr      
±³À°Á¾·ù : ³»°úÀÇ·áÀ±¸®ÇÐ
Âü¼®¿¹»óÀοø : 800¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 0ºÐ  
¼¼ºÎ¼ö°­·á : 50,000¿ø      
ºñ°í È¸¿ø : 3¸¸¿ø/ºñȸ¿ø (ÀüÀÓÀÇ/Àü°øÀÇ/¼®»ç±Þ ÀÌÇÏ ¿¬±¸¿ø ¹× Çлý/°£È£»ç/°øº¸ÀÇ/±ºÀÇ°ü/¾à»ç : 4¸¸¿ø, ±âŸ (°ü·Ã¾÷üÆ÷ÇÔ): 5¸¸¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 08-20 ¿Â¶óÀο¬¼ö±³À°(½Ç½Ã°£) 09:05~09:20 Changes in ASCO 2021  ¾ÈÁß¹è(¿¬¼¼¾Ïº´¿ø) 
±³À°½Ã°£ 08-20 ¿Â¶óÀο¬¼ö±³À°(½Ç½Ã°£) 09:20~09:50 Developmental Therapeutics  ÃÖ¿ë¿ø(¾ÆÁִ뺴¿ø) 
±³À°½Ã°£ 08-20 ¿Â¶óÀο¬¼ö±³À°(½Ç½Ã°£) 09:50~10:20 Gastric Cancer  Á¤¹Î±Ô(¿¬¼¼¾Ïº´¿ø) 
±³À°½Ã°£ 08-20 ¿Â¶óÀο¬¼ö±³À°(½Ç½Ã°£) 10:20~10:50 Update on Radiotherapy  ¹Ú½ÅÇü(°æºÏ´ëº´¿ø) 
±³À°½Ã°£ 08-20 ¿Â¶óÀο¬¼ö±³À°(½Ç½Ã°£) 10:50~11:20 Head & Neck / Esophageal Cancers / CNS Tumors  ±èÈ«ÁØ(°æÈñ´ëº´¿ø) 
±³À°½Ã°£ 08-20 ¿Â¶óÀο¬¼ö±³À°(½Ç½Ã°£) 11:20~11:50 Lung Cancer  ±èÇý·Ã(¿¬¼¼¾Ïº´¿ø) 
±³À°½Ã°£ 08-20 ¿Â¶óÀο¬¼ö±³À°(½Ç½Ã°£) 11:50~12:20 Ethics / Palliative Care  ¿ø¿µ¿õ(ÇѾç´ë±¸¸®º´¿ø) 
½Ä»ç 08-20 ¿Â¶óÀο¬¼ö±³À°(½Ç½Ã°£) 12:20~13:00 Lunch Break  () 
±³À°½Ã°£ 08-20 ¿Â¶óÀο¬¼ö±³À°(½Ç½Ã°£) 13:00~13:30 Liposomal irinotecan : New treatment option in pancreatic cancer  ÀüÈ«Àç(ºÐ´çÂ÷º´¿ø) 
±³À°½Ã°£ 08-20 ¿Â¶óÀο¬¼ö±³À°(½Ç½Ã°£) 13:30~14:00 Promises and challenges of NSCLC treatment with 3rd EGFR TKI LECLAZA¢ç  ¾ÈÁø¼®(»ï¼º¼­¿ïº´¿ø) 
±³À°½Ã°£ 08-20 ¿Â¶óÀο¬¼ö±³À°(½Ç½Ã°£) 14:00~14:30 Breast Cancer  Á¤ÀçÈ£(¼­¿ï¾Æ»êº´¿ø) 
±³À°½Ã°£ 08-20 ¿Â¶óÀο¬¼ö±³À°(½Ç½Ã°£) 01:00~01:00 GU / GY Cancers  Çã¼®Àç(µ¿¾Æ´ëº´¿ø) 
±³À°½Ã°£ 08-20 ¿Â¶óÀο¬¼ö±³À°(½Ç½Ã°£) 15:00~15:30 Lymphoma  ÃÖÁ¤Çý(ÇѾç´ë±¸¸®º´¿ø) 
È޽Ġ08-20 ¿Â¶óÀο¬¼ö±³À°(½Ç½Ã°£) 15:30~15:40 Break  () 
±³À°½Ã°£ 08-20 ¿Â¶óÀο¬¼ö±³À°(½Ç½Ã°£) 15:40~15:50 Amivantamab In Combination With Lazertinib For The Treatment Of Osimertinib-relapsed, Chemotherapy-naïve EGFR Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) and Potential Biomarkers For Response  Á¶º´Ã¶(¿¬¼¼¾Ïº´¿ø) 
±³À°½Ã°£ 08-20 ¿Â¶óÀο¬¼ö±³À°(½Ç½Ã°£) 15:50~16:00 Liposomal irinotecan (nal-IRI) in combination with fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic biliary tract cancer (BTC) after progression on gemcitabine plus cisplatin (GemCis): Multicenter comparative randomized phase 2b study (NIFTY).  À¯Ã¢ÈÆ(¼­¿ï¾Æ»êº´¿ø) 
±³À°½Ã°£ 08-20 ¿Â¶óÀο¬¼ö±³À°(½Ç½Ã°£) 16:00~16:10 A phase Ib trial of belvarafenib in combination with cobimetinib in patients with advanced solid tumors: Interim results of dose-escalation and patients with NRAS-mutant melanoma of dose-expansion.  ½Å»óÁØ(¿¬¼¼¾Ïº´¿ø) 
±³À°½Ã°£ 08-20 ¿Â¶óÀο¬¼ö±³À°(½Ç½Ã°£) 16:10~16:40 Colon Cancer  ·ùÇý¿ø(Ãæ³²´ëº´¿ø) 
±³À°½Ã°£ 08-20 ¿Â¶óÀο¬¼ö±³À°(½Ç½Ã°£) 16:40~17:10 Hepatobiliary / Pancreatic Cancers  ±èÀÏȯ(ÇØ¿î´ë¹éº´¿ø) 
±³À°½Ã°£ 08-20 ¿Â¶óÀο¬¼ö±³À°(½Ç½Ã°£) 17:10~17:40 Melanoma / Sarcoma  ±èÁ¤ÈÆ(°æ»ó´ëº´¿ø) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇÑÁ¾¾ç³»°úÇÐȸ (¿Â¶óÀÎ) Best of ASCO 2021 in Korea : 2021-08-20""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û (¿Â¶óÀÎ) ´ëÇѺ´¸®ÇÐȸ °øÅ뿪·®±³À° : 2021-08-21
´ÙÀ½±Û ´ëÇÑÀÓ»óÅëÁõÇÐȸ (¿Â¶óÀÎ) 2021³â Á¦2ȸ ¿Â¶óÀÎ Á¤±âÇмúÁý´ãȸ : 2021-08-20
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
495 °­¿ø ¿øÁÖ¼¼ºê¶õ½º±âµ¶º´¿ø NAFLD(non-alcoholic fatty liver disease) and Cardiometabolic Syndrome [7th Gangwon Heart Seminar 2018] : 2018-09-07 0 920 2018-08-22
494 ÀüºÏ ÀüÁÖ ¿¹¼öº´¿ø ´ëÇÑÀçÈ°ÀÇÇÐȸ È£³²Á¦ÁÖÁöȸ ÀçÈ° ½ÉÆ÷Áö¾ö : 2018-09-07 0 1,040 2018-08-22
493 ¼­¿ï ¼¼ºê¶õ½ºº´¿ø ¾È°ú ±Ý¿äÁý´ãȸ : 2018-09-07 0 850 2018-08-22
492 ¼­¿ï 2018³â °³¿øÀǸ¦ À§ÇÑ °­µ¿°æÈñ´ëÇб³º´¿ø ¼ÒÈ­±âÁúȯ ¿¬¼ö°­Á : 2018-09-06 0 681 2018-08-22
491 Ãæ³² ´Ü±¹´ëÇб³º´¿ø 2018³â Á¦3Â÷ ´ëÇѺ´¸®ÇÐȸ ´ëÀü¤ýÃæûÁöȸ: ÃÖ½ÅÀÇÇÐÁ¤º¸ Ư°­ ¹× º´¸®ÇÐ Áõ·Ê ¹ßÇ¥ : 2018-09-06 0 769 2018-08-22
490 ´ë±¸ ´ëÇѽŻý¾ÆÇÐȸ ´ë±¸°æºÏÁöȸ Áý´ãȸ : 2018-09-06 0 992 2018-08-22
489 Àü³² Á¦257Â÷ ´ëÇѳ»°úÇÐȸ ±¤ÁÖÀü³²Áöȸ Çмú´ëȸ : 2018-09-06 0 573 2018-08-22
488 °æ³² ´ëÇÑÇǺΰúÇÐȸ º£Ã¼Æ®º´ÀÇ ÃÖ½ÅÁö°ß¿¡ °üÇÏ¿© : 2018-09-06 0 717 2018-08-22
487 Ãæ³² °Ç¾ç´ëÇб³º´¿ø ´ëÇÑÇǺΰúÇÐȸ ÃæûÁöºÎÇÐȸ : 2018-09-06 0 897 2018-08-22
486 ´ë±¸ °è¸í´ëÇб³ µ¿»êÀÇ·á¿ø ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ Á¦234Â÷ °æºÏÁöȸ Áý´ãȸ : 2018-09-06 0 740 2018-08-22
485 °æ±â °¡Å縯´ëÇб³ ºÎõ¼º¸ðº´¿ø ´ëÇѺñ´¢±â°úÇÐȸ 2018 Á¦ 3Â÷ ÀÎõ.°æ±âÁöȸ Áý´ãȸ : 2018-09-06 2 1,467 2018-08-22
484 °æ³² ´ëÇÑÈäºÎ¿Ü°úÇÐȸ 2018³âµµ 3Â÷ ºÎ»ê¿ï»ê°æ³² ÈäºÎ¿Ü°ú Áý´ãȸ ¹× °­¿¬ : 2018-09-06 0 695 2018-08-22
483 ¼­¿ï ¼¼ºê¶õ½ºº´¿ø À̺ñÀÎÈÄ°ú 2Çбâ Áö¿ªÀÇ»çÁý´ãȸ : 2018-09-06 0 529 2018-08-22
482 ºÎ»ê ºÎ»ê±¤¿ª½ÃÀÇ»çȸ ¼­±¸ÀÇ»çȸ 9¿ù Çмúȸ : 2018-09-05 0 635 2018-08-22
481 ´ë±¸ 2018³â ´ëÇÑ°¨¿°ÇÐȸ ¿µ³²Áöȸ 9¿ù Áý´ãȸ : 2018-09-05 0 476 2018-08-22
1371 | 1372 | 1373 | 1374 | 1375 | 1376 | 1377 | 1378 | 1379 | 1380
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷